搜索
129Vol.12No.920069NationalJournalofAndrologySep.20061,1,1,2,2,3,3,3(1.,430030;2.,310003;3.,100034):::,Stamey(EPS)(NIH2CPSI),160,(80,1)(80)4,4,2/d,1/,2/d,0.1g/;,48NIH2CPSIEPS:48,3.342.45,4.333.13,2.221.79,2.772.04;2.282.42,3.303.29,1.241.67,1.832.25(P0.01),(P0.05),48(P0.01P0.05)(P0.05),(P0.05),:,,:;;:R697+.33:A:100923591(2006)0920807204AClinicalStudyofProstatCombinedwithanAntibioticforChronicNonbacterialProstatitisYEZhang2qun1,LANRu2zhu1,WANGShao2gang1,CAISong2liang2,CHENGe2ming2,LINing2chen3,SONGYi3,NAYan2qun31.DepartmentofUrology,TongjiHospitalAffiliatedtoTongjiMedicalCollege,HuazhongUniversityofScience&Technology,Wuhan,Hubei430030,China;2.DepartmentofUrology,theFirstAffiliatedHospitalofZhejiangUni2versitySchoolofMedicine,Hangzhou,Zhejiang210003,China;3.InsituteofUrology,PekingUniversityFirstHos2pital,Beijing100034,ChinaCorrespondenceto:YEZhang2qunAbstract:Objective:ToevaluatetheefficacyandsafetyofProstatincombinationwithanantibioticforthetreatmentofchronicnon2bacterialprostatitis.Methods:Adouble2blind,parallelcontrasted,multi2centralmethodwasappliedinthestudy.AftertheStamey708:2006204205;:2006206210:(19542),,,,,:©1994-2007ChinaAcademicJournalElectronicPublishingHouse.Allrightsreserved.(EPS)examination,160patientswithprostatitiswererecruitedandrandomizedintoatrialgroup(80caseswith1casemissing)andacontrolgroup(80cases).Inthetrialgroup,thepatientsusedthelevofloxacinandProstatduringthefirst4weeksandProstatonlyduringthefollowing4weeks.Inthecontrolgroup,thepatientsusedthelevofloxacinandplacebodur2ingthefirst4weeks,andplaceboonlyduringthefollowing4weeks.Beforeand4and8weeksafterthetreatment,thepatientswerevisitedandevaluatedbythenationalinstitutehealth2chronicprostatitssymptomindex(NIH2CPSI),EPS,andaskedaboutthesideeffects.Results:After42weekand82weektreatment,thepainindexdroppedby3.342.45and4.063.03inthetrialgroup,and2.282.42and3.303.29inthecontrol;thevoidingindexdroppedby2.221.79and2.772.04inthetrialgroup,and1.241.67and1.832.25inthecontrolrespectively.Therewassignificantdifferencebetweenpre2treatmentandpost2treatmentinboththetwogroups(P0.01),whilethedifferencewasnotsignificantbetween42weekand82weekpost2treatment(P0.05).Andtherewassignificantdifferencebetweenthetwogroupsinthepainindexandvoidingindex(P0.01),butnotinthewhitebloodcellcountandlipidintheEPS(P0.05).Noserioussideeffectswererecorded,andthetolerancetoProstatandplaceboshowednosignigicantdifference.Conclusion:Prostatincombinationwithanantibioticcaneffectivelyrelievethepainandvoidingsymptomsandimprovethelifequalityofthepatientswithnonbacterialprostatitisandwelldeservestoberecommendedinclinicalpractice.NatlJAndrol,2006,12(9):8072810Keywords:chronicprostatitis;clinicaltrial;Prostat(Prostat),,[1,2],,,2005920063311.11.1.11.1.2,7d(),48,1.1.34,4,2/d,1/,2/d,1/;,,0.375g/(70mgP54mgEA10),,:20050304,2,0.1g/,:20050402,1.21.2.11.2.1.1(NIH2CPSI)10;6,(EPS)(WBC)10/HP;6;1850;2;,11.2.1.2;;;;;;;;1.2.21.2.2.1,1.2.2.23d,;,,;()1.3::NIH2CPSI,:WBC(LPS)48,8082006912©1994-2007ChinaAcademicJournalElectronicPublishingHouse.Allrightsreserved.:1.4t,Cohran2Matel2Haenszel(CMH22)WBCLPS,P0.052160:79,1,80(31.238.03),(2.551.92);(31.846.39),(2.181.96)EPS(P0.05)()48(P0.01)(1),48,(P0.01P0.05)(2),(P0.05)84(P0.05)EPSWBCLPS(P0.05),CMH22(P0.05)1(xs)Table1.ComparisonofNIH2CPSIindexbetweenpre2andpost2treatmentinthetwogroups(xs)Indexw0Group1Group2w4Group1Group2w8Group1Group2Pain8.393.828.462.945.053.1636.193.1234.063.0335.163.243Urination4.352.454.242.262.141.7833.002.1331.581.5132.411.963Lifequality8.562.419.718.315.772.5837.352.2834.752.8436.132.923Severity12.714.3012.704.217.193.8139.194.1235.673.6837.584.243Group1:;Group2:;w0:;w4:4;w8:8;,:P0.05,:P0.01;,3:P0.01Group1:Trial;Group2:control;w0:beforetreatment;w4:42weekaftertreatment;w8:82weekaftertreatment;comparedwiththecontrolgroup,:P0.05,:P0.01;comparedwithpre2treatment,3:P0.012(xs)Table2.ComparisonofthechangesofNIH2CPSIindexaftertreatmentinthetwogroups(xs)Indexw024Group1Group2w028Group1Group2w428Group1Group2Pain3.342.452.282.424.333.1333.303.20.991.671.032.35Urination2.221.791.241.672.772.041.832.250.561.030.591.46Lifequality2.792.192.368.463.812.713.598.611.031.831.232.06Severity5.523.253.513.317.043.995.134.491.522.351.613.14Group1:;Group2:;w024:4;w028:8;w428:84,3:P0.05,:P0.01Group1:Trial;Group2:control;w0:changesafter42weektreatment;w028:changesafter82weektreatment;w428:changesfrom42weekto82weektreatment;comparedwiththecontrolgroup,3:P0.05,:P0.019089©1994-2007ChinaAcademicJournalElectronicPublishingHouse.Allrightsreserved.[3]5:I,II,III,(CPPS),,IV[4]NIH2CPSI,,,,,48NIH2CPSI,,,(),48,84,,,,1EPSWBCLPS,WBCLPS,EPSWBCLPS[5],2,,2,,100%,P5EA10,P5EA10,,;,,[6],[1,2],,,,:,,,,(:3,,!)[1]ElistJ.EffectsofpollenextractpreparationProstat/Poltitonlow2erurinarytractsymptomsinpatientswithchronicnonbacterialprostatitis/chronicpelvicpainsyndrome:arandomized,double2blind,placebo2controlledstudy[J].Urology,2006,67(1):60263.[2],,,.[J].,2003